Table 3.
The concentration of catecholamines in plasma after 4-AP, 3,4-DAP, and nicotine.
| Groups | WKY |
SHR |
||
|---|---|---|---|---|
| Norepinephrine (nM) | Epinephrine (nM) | Norepinephrine (nM) | Epinephrine (nM) | |
| Time controls (PBS + PBS)a | 0.5 ± 0.1 | 8.1 ± 1.5 | 1.2 ± 0.2‡ | 13.2 ± 2.5 |
| PBS + 4-AP | 2.2 ± 0.2* | 10.2 ± 2.1 | 8.3 ± 1.0*,‡ | 9.5 ± 1.8 |
| PBS + 3,4-DAP | 1.4 ± 0.1*† | 10.1 ± 1.8 | 6.0 ± 0.7*,‡ | 20.2 ± 4.7 |
| Hemicholinium-3 + 3,4-DAP | 0.8 ± 0.2├ | 4.2 ± 2.6 | 2.7 ± 0.4├ | 5.3 ± 1.4 |
| Hexamethonium + 3,4-DAP | Not measured | 2.5 ± 0.3├ | 3.4 ± 0.9├ | |
| Atropine + 3,4-DAP | Not measured | 12.9 ± 3.1├ | 18.6 ± 7.8 | |
| Reserpine + 3,4-DAP | 0.0 ± 0.0├ | 5.5 ± 3.7 | Not measured | |
| Reserpine + atropine + 3,4-DAP | 0.0 ± 0.0├ | 6.9 ± 1.1 | Not measured | |
| Nadolol + 3,4-DAP | 0.3 ± 0.3├ | 5.5 ± 0.8 | 6.8 ± 2.6 | 14.7 ± 8.9 |
| Atropine + nadolol + 3,4-DAP | Not done | 9.0 ± 1.8 | 54.0 ± 15.5 | |
| Quinidine + 3,4-DAP | Not done | 4.1 ± 1.1├ | 11.4 ± 3.2 | |
| Nicotine | 2.1 ± 0.3* | 3.1 ± 0.7* | 1.4 ± 0.3 | 3.7 ± 2.1* |
| 3,4-DAP + nicotine | Not done | 12.0 ± 1.3├ | 26.1 ± 6.0 | |
Significant differences between the time-control and the 4-AP/3,4-DAP/nicotine control groups (*), between the 4-AP and 3,4-DAP control groups within each strain (†), between corresponding WKY and SHR PBS/4-AP/3,4-DAP controls (‡ after SHR values), and between corresponding 3,4-DAP control and experimental groups (├), were detected as indicated.
aFrom Ref. (10), run in part intermittently with the present 4-AP and 3,4-DAP control groups. N = 4–9 rats per group, but 20 in the 4-AP-groups.
*, †, ‡, ├P < 0.05.